Skip to content
Baret News – Lifestyle
Author:
CRISPR Therapeutics AG
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
August 28, 2026
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 3, 2026
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
May 28, 2026
←
Previous Page
1
2